Abstract
Background
A combination of genetic and environmental factors is involved in the etiology of inflammatory bowel disease (IBD). Recent studies have shown that adipocytes play a crucial role, by actively participating in systemic immune responses in IBD patients. But findings remain controversial. To the best of our knowledge, no systematic review has evaluated the roles of adipokines in IBD, considering which this systematic review was undertaken to summarize the effects of these adipokines in IBD pathogenesis.
Methods
For this review, articles published between 1980 and 2016 were identified from the PubMed, EMBASE, Scopus, and Cochrane and Google scholar databases. Thirteen articles were ultimately selected for inclusion in this systematic review.
Results
Findings of the present study indicate that some of the adipokines such as leptin, adiponectin and resistin are associated with disease severity, body composition and glucose hemostasis in IBD patients, although some of these associations are stronger than others.
Conclusions
Overall findings indicate that some adipokines may play a crucial role in IBD severity or other IBD related outcomes. Further studies are recommended to confirm the results.
Similar content being viewed by others
References
Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.
Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22:382–389.
Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014;37:1337–1353.
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong M-L, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol. 2012;56:597–607.
Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987–991.
Singh UP, Singh NP, Guan H, et al. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014;33:23–33.
Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol.. 2016;8:101–109.
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.
Ghomraoui FA, Alotaibi ST, Alharthi MA, et al. Plasma ghrelin and leptin in patients with inflammatory bowel disease and its association with nutritional status. Saudi J Gastroenterol. 2017;23:199–205. PubMed PMID: 28611344. Pubmed Central PMCID: PMC5470380. Epub 06/15/2017. eng.
Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12.
Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–1758.
Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28:814–819.
Laiguillon M-C, Houard X, Bougault C, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther. 2014;16:R38.
Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10. PubMed PMID: 25594108. Epub 01/17/2015. eng.
Aurangzeb B, Leach ST, Lemberg DA, Day AS. Assessment of nutritional status and serum leptin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:536–541.
Bannerman E, Davidson I, Conway C, Culley D, Aldhous M, Ghosh S. Altered subjective appetite parameters in Crohn’s disease patients. Clin Nutr. 2001;20:399–405.
Tuzun A, Uygun A, Yesilova Z, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19:429–432.
Rodrigues V, Milanski M, Fagundes J, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn’s disease. Clin Exp Immunol. 2012;170:358–364.
Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25:172–181.
Dogan S, Guven K, Celikbilek M, Deniz K, Saraymen B, Gursoy S. Serum visfatin levels in ulcerative colitis. J Clin Lab Anal. 2015;30:552–556.
Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–1074.
Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010;16:630–637.
Chouliaras G, Panayotou I, Margoni D, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn’s disease and ulcerative colitis. Pediatr Res. 2013;74:420–426.
Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–105.
Abdel Kader N, Ali El-Din F, Khatab EA, ELAbd N. Does plasma resistin level have a role in predicting inflammatory bowel disease activity? Indian J Gastroenterol. 2010;29:126–127.
Ahishali E, Ercan S, Dolapcioglu C, Dabak R, Kaptanagasi A, Bayramicli O. P140 The relation between resistin and insulin resistance in inflammatory bowel disease patients. J Crohn’s Colitis. 2012;6:S65–S66.
Bruun JM, Pedersen SB, Kristensen K, Richelsen B. Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 2002;190:91–99.
Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab. 2005;90:3510–3516.
Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. Unraveling the link between leptin, ghrelin and different types of colitis. Ann Gastroenterol. 2011;24:20–28. PubMed PMID: 24714276. Pubmed Central PMCID: PMC3959465. Epub 01/01/2011. eng.
Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007;455:479–492. PubMed PMID: 17609976. Pubmed Central PMCID: PMC2040175. Epub 07/05/2007. eng.
Neumeier M, Weigert J, Schäffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79:803–808.
Yamaguchi N, Argueta JGM, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005;579:6821–6826.
Kaser A, Tilg H. “Metabolic aspects” in inflammatory bowel diseases. Curr Drug Deliv. 2012;9:326–332.
Paul G, Schäffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn’s disease. Inflamm Bowel Dis. 2006;12:471–477.
Kaser S, Kaser A, Sandhofer A, Ebenbichler C, Tilg H, Patsch J. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–290.
Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–1101.
Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–2921.
Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.
Scoville AE, Brown C, Allaman M, et al. Differences in serum adipokines between Crohn’s disease and ulcerative colitis patients indicate that they may represent non-invasive biomarker. Gastroenterology. 2016;150:380–389.
Acknowledgment
The authors wish to acknowledge Ms. Niloofar Shiva for critical editing of English grammar and syntax of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing financial interests relevant to the present work.
Rights and permissions
About this article
Cite this article
Morshedzadeh, N., Rahimlou, M., Asadzadeh Aghdaei, H. et al. Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews. Dig Dis Sci 62, 3280–3286 (2017). https://doi.org/10.1007/s10620-017-4806-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-017-4806-5